Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Atopic Dermatitis | Emerging Therapies | Eucrisa (crisaborole) | US | Wave 2 | 2017

Login to access report north_east
Contact sales account_box

Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What is U.S. dermatologists’ awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
  • What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?

Methodology: ~75 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Eucrisa

Key companies: Pfizer

Related reports: Atopic Dermatitis | Disease Landscape and Forecast | US/EU/Japan, Atopic Dermatitis | Unmet Need | US/EU, Atopic Dermatitis | Access and Reimbursement | US, Atopic Dermatitis | Access and Reimbursement | EU5, Atopic Dermatitis | Current Treatment | EU5

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
north_east
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
north_east
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
north_east
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east